United States - English - NLM (National Library of Medicine)

doh central pharmacy - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - norvir tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. norvir oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with hiv-1 infection. - when co-administering norvir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - norvir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - norvir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. - norvir is contraindicated with drugs that are potent cyp3a inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possib

United States - English - NLM (National Library of Medicine)

abbvie inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 100 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to kaletra [see microbiology ( 12.4 )] . - kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - kaletra is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions ( 7.1 ) and clinical pharmacology ( 12.3 )] . ○ alpha 1- adrenoreceptor antagonist: alfuzosin ○ antianginal: ranolazine ○ antiar

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - ritonavir; lopinavir -

Israel - English - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ritonavir - film coated tablets - ritonavir 100 mg - ritonavir - ritonavir - is indicated alone or in combination with other antiretroviral agents for the treatment of patients with hiv infection when therapy is warranted based on clinical and/or immunological evidence of disease progression

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

mylan laboratories limited, india - darunavir , ritonavir - tablets - 400/50 mg

Uganda - English - National Drug Authority

mylan laboratories limited- - darunavir ethanolate + ritonavir - oral solid ordinary film-coated tablets - 400 mg + 50 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

mylan laboratories limited, india - lopinavir , ritonavir - tablets - 250

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - lopinavir 200 mg; ritonavir 50 mg - film-coated tablet - lopinavir and ritonavir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - lopinavir 200 mg; ritonavir 50 mg - film-coated tablet - lopinavir and ritonavir

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - lopinavir 200 mg; ritonavir 50 mg - film-coated tablet - lopinavir and ritonavir